NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS
FOR: PROCYON BIOPHARMA INC.
CDNX SYMBOL: PBP
JANUARY 27, 2000
Procyon Announces Board Changes: Dr. Bernard Coupal Joins
Board of Procyon BioPharma
MONTREAL, QUEBEC--Procyon BioPharma Inc.("Procyon") announces the
appointment to its Board of Dr. Bernard Coupal, President of T2C2,
representing the Societe Innovatech du Grand Montreal.
"I am pleased and honored that a person of Dr. Coupal's stature, a
key figure in Quebec's financial and biotechnology communities,
has agreed to join our board and add his expertise to assist in
Procyon's development," stated Mr. Hans J. Mader, Procyon's
President and CEO.
Before joining T2C2, Dr. Coupal acted as President and General
Manager of the Societe Innovatech du Grand Montreal, a company he
created in 1992 after taking part in the creation of BioCapital, a
venture capital company in the biotechnology sector. Earlier he
was the first Director-General of the National Research Council of
Canada's Biotechnology Research Institute and assumed various
management positions with companies specializing in new
technologies.
At the same time, Mr. William R. McMahan, President and CEO of
Oxbow Equities Corp., will be leaving the Board due to other
commitments. "I want to thank Mr. McMahan for his excellent
contribution to Procyon during his tenure and I wish him the best
in his future endeavors," said Mr. Mader.
"Procyon has reached a very important stage in its development
with two near-term products approaching commercialization and
intensive R&D efforts on its two core technologies. The quality
of this Board with its excellent balance of scientific and
business expertise obtained both in Europe and North America,
provides the Company with a strong foundation of expert counsel,"
Mr. Mader added.
/T/
Procyon Biopharma's Board of Directors
Below is a list of the other members of the Board of Procyon
Biopharma:
* James Youmans, Chairman of the Board of Procyon and former COO of
Novartis International in Switzerland: over 25 years experience
in the international pharmaceutical industry.
* Dr. Phil Gold, Executive Director, Clinical Research Centre,
Montreal General Hospital - McGill University Health Center: 30
years experience in clinical medicine and research and an
acknowledged expert in the field of oncology.
* Charles Bernie (Bud) Johnston, Jr.: former Dean of the Ivey
School of Business at the University of Western Ontario: vast
business management experience;
* Dr. Max Link, former Chairman and CEO of Sandoz Pharma Ltd. and
the former CEO of Corange, Ltd.: strong North American and
European experience in biotechnology and pharmaceuticals;
* William MacDonald Jr., Vice-President, Investments and Portfolio
Management, Dolmac Holdings Ltd.: extensive American business
experience;
* lain Maclnnes, co-founder of Procyon Biopharma and Vice President
with National Bank Financial;
* Hans J. Mader, President and CEO, Procyon Biopharma: broad North
American and European management experience in the pharmaceutical
industry.
* Dr. Chandra J. Panchal, Executive Vice-President and co-founder
of Procyon Biopharma: enormous experience in scientific research
and development;
/T/
Procyon BioPharma Inc. is a publicly listed, biopharmaceutical
company focused principally on advancing two powerful platform
technologies that have the potential to diagnose and treat cancer.
Procyon's Antinuclear Autoantibodies (ANAs) bind specifically to
multiple cancer cell types strongly enhancing the immune response
to cancer cells. Prostate Secretory Protein (PSP94) is a
naturally occurring human protein that has the potential to treat
prostate cancer by inhibiting abnormal prostate cell growth.
Procyon also has two late-stage products: FIBROSTAT(TM), a topical
cream for the management of newly formed scars following surgery
or burns and COLOPATH(TM), a rapid, non-invasive screening test
for colorectal cancer.
Procyon's shares trade on the CDNX under the ticker symbol, PBP.
The CDNX has neither approved or disapproved the information
contained in this release.
|
